Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Chemotherapy-induced Nausea and Vomiting: full-pipeline trial registry
1 of 4 indexed Chemotherapy-induced Nausea and Vomiting trials are currently recruiting.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Chemotherapy-induced Nausea and Vomiting: 4 US clinical trials tracked, 1 recruiting.
Chemotherapy-induced Nausea and Vomiting is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Kyowa Kirin Pharmaceutical Development, running 1 of these trials.
Enrollment posture brief
Registry condition chemotherapy-induced-nausea-and-vomiting
OPEN 1 | RECR 25% | LATE 1 | EARLY 1 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Chemotherapy-induced Nausea and Vomiting lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Chemotherapy-induced Nausea and Vomiting on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Chemotherapy-induced Nausea and Vomiting is recruiting below its size-band peers.
1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Serious Gaming for Chemotherapy-induced Nausea and Vomiting
University of Central Florida
NCT05838638
Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy
Tesaro
NCT01499849
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
University of South Florida
NCT01346267
Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years
Kyowa Kirin Pharmaceutical Development
NCT01596400
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Chemotherapy-induced Nausea and Vomiting records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Chemotherapy-induced Nausea and Vomiting trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Chemotherapy-induced Nausea and Vomiting page
4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Chemotherapy-induced Nausea and Vomiting trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Kyowa Kirin Pharmaceutical Development sponsors the most Chemotherapy-induced Nausea and Vomiting trials on record, review their full trial history before evaluating a specific study. See Kyowa Kirin Pharmaceutical Development's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Chemotherapy-induced Nausea and Vomiting condition card totals 4 registered trials; most-linked intervention Placebo Acupressure Band; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.